{"id":58056,"date":"2024-02-09T11:05:50","date_gmt":"2024-02-09T11:05:50","guid":{"rendered":"https:\/\/news.pakistaninewspaperlist.com\/adagene-announces-progress-and-expansion-of-clinical-collaboration-program-for-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-keytruda-pembrolizumab-to-demonstrate\/"},"modified":"2024-02-09T11:05:50","modified_gmt":"2024-02-09T11:05:50","slug":"adagene-announces-progress-and-expansion-of-clinical-collaboration-program-for-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-keytruda-pembrolizumab-to-demonstrate","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/adagene-announces-progress-and-expansion-of-clinical-collaboration-program-for-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-keytruda-pembrolizumab-to-demonstrate\/","title":{"rendered":"Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with KEYTRUDA\u00ae (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)"},"content":{"rendered":"
\n

–<\/em>\u00a0Interim data from additional MSS CRC patients dosed at 10 mg\/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference\u00a0–<\/em><\/em><\/p>\n

–<\/em>\u00a0Initiated evaluation of 20 mg\/kg loading doses of ADG126 in combination with pembrolizumab to explore enhanced efficacy given superior therapeutic index of ADG126\u00a0–<\/em><\/em><\/p>\n

–<\/em>\u00a0Received clearance from China\u2019s Center for Drug Evaluation (CDE) to evaluate ADG126 in combination with pembrolizumab\u00a0–<\/em><\/em><\/p>\n

SAN DIEGO and SUZHOU, China, Feb. 09, 2024 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae<\/sup> (pembrolizumab), in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).<\/p>\n

\u201cFollowing completion of enrollment of 12 additional patients at the end of last year, together with our ongoing expansion plans, we are on track to deliver data in 2024 that support the findings released at the recent ASCO-GI Symposium demonstrating the safety and efficacy profile of ADG126 in combination with pembrolizumab in MSS CRC,\u201d said Peter Luo, Ph.D., Chairman, CEO and President of R&D at\u00a0Adagene.<\/p>\n

He continued, \u201cTo address the requirements for Project Optimus by FDA, we have initiated evaluation of ADG126 20 mg\/kg loading doses in combination with pembrolizumab, which we believe can unlock even greater efficacy for MSS CRC in planned cohort expansion, while still maintaining a robust safety profile. Additionally, we are now cleared to evaluate ADG126 in combination with pembrolizumab in China, strengthening our efficacy evaluation with additional patients enrolled at unprecedented dosing regimens for anti-CTLA-4 therapy.\u201d<\/p>\n

The updates, which increase the ongoing phase 2 dose expansion in MSS CRC to over 50 patients, include the following:<\/p>\n